100 related articles for article (PubMed ID: 23142617)
1. Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part I.
Furber M; Alcaraz L; Luckhurst C; Bahl A; Beaton H; Bowers K; Collington J; Denton R; Donald D; Kinchin E; MacDonald C; Rigby A; Riley R; Soars M; Springthorpe B; Webborn P
Bioorg Med Chem Lett; 2012 Dec; 22(24):7702-6. PubMed ID: 23142617
[TBL] [Abstract][Full Text] [Related]
2. Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part II: optimising in vivo clearance.
Furber M; Alcaraz L; Luckhurst C; Bahl A; Beaton H; Bowers K; Collington J; Denton R; Donald D; Kinchin E; MacDonald C; Rigby A; Riley R; Soars M; Springthorpe B; Webborn P
Bioorg Med Chem Lett; 2012 Dec; 22(24):7707-10. PubMed ID: 23116889
[TBL] [Abstract][Full Text] [Related]
3. The discovery of CCR3/H1 dual antagonists with reduced hERG risk.
Bahl A; Barton P; Bowers K; Brough S; Evans R; Luckhurst CA; Mochel T; Perry MW; Rigby A; Riley RJ; Sanganee H; Sisson A; Springthorpe B
Bioorg Med Chem Lett; 2012 Nov; 22(21):6688-93. PubMed ID: 23031591
[TBL] [Abstract][Full Text] [Related]
4. Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.
Bahl A; Barton P; Bowers K; Caffrey MV; Denton R; Gilmour P; Hawley S; Linannen T; Luckhurst CA; Mochel T; Perry MW; Riley RJ; Roe E; Springthorpe B; Stein L; Webborn P
Bioorg Med Chem Lett; 2012 Nov; 22(21):6694-9. PubMed ID: 23021991
[TBL] [Abstract][Full Text] [Related]
5. A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor.
Suzuki K; Morokata T; Morihira K; Sato I; Takizawa S; Kaneko M; Takahashi K; Shimizu Y
Eur J Pharmacol; 2007 Jun; 563(1-3):224-32. PubMed ID: 17336292
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, biological evaluation, and metabolic stability of acrylamide derivatives as novel CCR3 antagonists.
Sato I; Morihira K; Inami H; Kubota H; Morokata T; Suzuki K; Ohno K; Iura Y; Nitta A; Imaoka T; Takahashi T; Takeuchi M; Ohta M; Tsukamoto S
Bioorg Med Chem; 2009 Aug; 17(16):5989-6002. PubMed ID: 19620010
[TBL] [Abstract][Full Text] [Related]
7. Rodent selectivity of piperidine-4-yl-1H-indoles, a series of CC chemokine receptor-3 (CCR3) antagonists: insights from a receptor model.
Kriegl JM; Martyres D; Grundl MA; Anderskewitz R; Dollinger H; Rast G; Schmid B; Seither P; Tautermann CS
Bioorg Med Chem Lett; 2015 Jan; 25(2):229-35. PubMed ID: 25497216
[TBL] [Abstract][Full Text] [Related]
8. Pyrazolone methylamino piperidine derivatives as novel CCR3 antagonists.
Pégurier C; Collart P; Danhaive P; Defays S; Gillard M; Gilson F; Kogej T; Pasau P; Van Houtvin N; Van Thuyne M; van Keulen B
Bioorg Med Chem Lett; 2007 Aug; 17(15):4228-31. PubMed ID: 17532633
[TBL] [Abstract][Full Text] [Related]
9. Small molecule antagonists for chemokine CCR3 receptors.
Willems LI; Ijzerman AP
Med Res Rev; 2010 Sep; 30(5):778-817. PubMed ID: 19967721
[TBL] [Abstract][Full Text] [Related]
10. Discovery and structure-activity relationships of urea derivatives as potent and novel CCR3 antagonists.
Nitta A; Iura Y; Tomioka H; Sato I; Morihira K; Kubota H; Morokata T; Takeuchi M; Ohta M; Tsukamoto S; Imaoka T; Takahashi T
Bioorg Med Chem Lett; 2012 Aug; 22(15):4951-4. PubMed ID: 22749826
[TBL] [Abstract][Full Text] [Related]
11. The discovery of BMS-457, a potent and selective CCR1 antagonist.
Gardner DS; Santella JB; Duncia JV; Carter PH; Dhar TG; Wu H; Guo W; Cavallaro C; Van Kirk K; Yarde M; Briceno SW; Grafstrom RR; Liu R; Patel SR; Tebben AJ; Camac D; Khan J; Watson A; Yang G; Rose A; Foster WR; Cvijic ME; Davies P; Hynes J
Bioorg Med Chem Lett; 2013 Jul; 23(13):3833-40. PubMed ID: 23707259
[TBL] [Abstract][Full Text] [Related]
12. From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part II: Acyclic replacements for the (3S)-3-benzylpiperidine in a series of potent CCR3 antagonists.
Gardner DS; Santella JB; Tebben AJ; Batt DG; Ko SS; Traeger SC; Welch PK; Wadman EA; Davies P; Carter PH; Duncia JV
Bioorg Med Chem Lett; 2008 Jan; 18(2):586-95. PubMed ID: 18160284
[TBL] [Abstract][Full Text] [Related]
13. From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis.
Santella JB; Gardner DS; Yao W; Shi C; Reddy P; Tebben AJ; DeLucca GV; Wacker DA; Watson PS; Welch PK; Wadman EA; Davies P; Solomon KA; Graden DM; Yeleswaram S; Mandlekar S; Kariv I; Decicco CP; Ko SS; Carter PH; Duncia JV
Bioorg Med Chem Lett; 2008 Jan; 18(2):576-85. PubMed ID: 18096386
[TBL] [Abstract][Full Text] [Related]
14. CCR3 antagonists: a survey of the patent literature.
Gong L; Wilhelm RS
Expert Opin Ther Pat; 2009 Aug; 19(8):1109-32. PubMed ID: 19637977
[TBL] [Abstract][Full Text] [Related]
15. Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.
De Lucca GV; Kim UT; Vargo BJ; Duncia JV; Santella JB; Gardner DS; Zheng C; Liauw A; Wang Z; Emmett G; Wacker DA; Welch PK; Covington M; Stowell NC; Wadman EA; Das AM; Davies P; Yeleswaram S; Graden DM; Solomon KA; Newton RC; Trainor GL; Decicco CP; Ko SS
J Med Chem; 2005 Mar; 48(6):2194-211. PubMed ID: 15771462
[TBL] [Abstract][Full Text] [Related]
16. Urea based CCR3 antagonists employing a tetrahydro-1,3-oxazin-2-one spacer.
Dhar TG; Yang G; Davies P; Malley MF; Gougoutas JZ; Wu DR; Barrish JC; Carter PH
Bioorg Med Chem Lett; 2009 Jan; 19(1):96-9. PubMed ID: 19010676
[TBL] [Abstract][Full Text] [Related]
17. The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.
Procopiou PA; Browning C; Buckley JM; Clark KL; Fechner L; Gore PM; Hancock AP; Hodgson ST; Holmes DS; Kranz M; Looker BE; Morriss KM; Parton DL; Russell LJ; Slack RJ; Sollis SL; Vile S; Watts CJ
J Med Chem; 2011 Apr; 54(7):2183-95. PubMed ID: 21381763
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, structure-activity relationship and in vivo antiinflammatory efficacy of substituted dipiperidines as CCR2 antagonists.
Xia M; Hou C; DeMong DE; Pollack SR; Pan M; Brackley JA; Jain N; Gerchak C; Singer M; Malaviya R; Matheis M; Olini G; Cavender D; Wachter M
J Med Chem; 2007 Nov; 50(23):5561-3. PubMed ID: 17929797
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationships of N-{1-[(6-fluoro-2-naphthyl)methyl]piperidin-4-yl}benzamide derivatives as novel CCR3 antagonists.
Sato I; Morihira K; Inami H; Kubota H; Morokata T; Suzuki K; Hamada N; Iura Y; Nitta A; Imaoka T; Takahashi T; Takeuchi M; Ohta M; Tsukamoto S
Bioorg Med Chem; 2008 Jan; 16(1):144-56. PubMed ID: 17951061
[TBL] [Abstract][Full Text] [Related]
20. 2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.
Watson PS; Jiang B; Harrison K; Asakawa N; Welch PK; Covington M; Stowell NC; Wadman EA; Davies P; Solomon KA; Newton RC; Trainor GL; Friedman SM; Decicco CP; Ko SS
Bioorg Med Chem Lett; 2006 Nov; 16(21):5695-9. PubMed ID: 16931001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
